Creating digital models to discover new treatments for Alzheimer's disease
Official title: Precision Medicine Digital Twins for Alzheimer’s Target and Drug Discovery and Longevity
Funded at Cleveland Clinic Lerner Com-Cwru · NIH-10727793 · Data updated 2026-11-12
This study is working on a new way to find better treatments for Alzheimer's by creating digital models that help researchers understand the disease and discover new drug targets, which could lead to more effective therapies for patients.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cleveland Clinic Lerner Com-Cwru NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project start | August 15, 2023 |
| Project end | August 14, 2025 |
| Funding year | 2023 |
| Award (this year) | $482,520 |
| NIH project number | 1R21AG083003-01 |
| Project ID | NIH-10727793 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with Alzheimer's disease or those at risk of developing it.
✕Less likely to help
Patients with other forms of dementia unrelated to Alzheimer's may not receive benefits from this research.
What this research studies
This research focuses on developing advanced computational models, known as digital twins, to identify and prioritize potential drug targets for Alzheimer's disease. By utilizing a platform called AlzGPS, the team aims to integrate various biological data to enhance drug discovery processes. The project also includes creating a detailed map of brain cells to better understand the disease's progression and identify effective treatments. Patients may benefit from this innovative approach as it seeks to uncover new therapeutic options for Alzheimer's.
Why it matters
Potential benefit: If successful, this research could lead to the discovery of effective treatments that modify the progression of Alzheimer's disease.
How similar studies have gone: Previous research has shown promise in using digital models for drug discovery in other diseases, indicating potential success for this novel approach in Alzheimer's.
Where this research is happening
-
Cleveland Clinic Lerner Com-Cwru
Cleveland, United States Active
Researchers
- Principal investigator: Cheng, Feixiong — Cleveland Clinic Lerner Com-Cwru
- Study coordinator: Cheng, Feixiong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.